Navigation Links
Pharmasset to Present at JMP Securities Healthcare Conference
Date:10/1/2009

PRINCETON, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the JMP Securities Healthcare Conference. The conference will be held at the New York Palace Hotel in New York City (October 5-6, 2009).

Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company on Tuesday, October 6, 2009 at 1:30 PM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following each presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which has completed Phase 1 clinical studies, and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial.

Pegasys(®) and Copegus(® )are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended June 30, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

SOURCE Pharmasset, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmasset Reports Fiscal Third Quarter 2009 Financial Results
2. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
3. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
4. Pharmasset to Present at Deutsche Bank Healthcare Conference
5. Pharmasset to Present at Two Upcoming Investor Conferences
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
8. Pharmasset to Webcast an Investor Event from the AASLD Meeting
9. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
10. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
11. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare ... San Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop ... habits. The workshops cover a broad range of topics, including coaching skills, the ...
(Date:2/12/2016)... ... 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined Governor ... Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System yesterday ... This will be the first Fisher House in Nevada, and will provide free lodging ...
(Date:2/12/2016)... ... ... Vail knee specialist Robert LaPrade, MD, PhD was named one of ... of physicians establishing, leading and partnering with ambulatory surgery centers across the United States. ... also known as an ASC, is a modern health care facility focused on providing ...
(Date:2/12/2016)... ... ... Donor Network West, the organ procurement organization that heals lives through organ ... Regional Medical Center. Under the collaboration, the first of its kind, specific organ donors ... certain time frame for donor families for the recovery of organs. , Organ ...
(Date:2/12/2016)... ... 12, 2016 , ... J Thomas & Associates Insurance Agency, ... to act as Agents of Change in the community, announces a new partnership ... to fulfill immediate needs and help them move into permanent housing. Donations to ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
(Date:2/11/2016)... 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2015. The Company also filed its Quarterly Report on Form ... the Securities and Exchange Commission today. --> ... --> --> Net sales for ... or 95%, to $5.4 million from $2.8 million for the ...
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. ... saving and improving the lives of pets, today announced ... of the New Animal Drug Application (NADA) for Zimeta™ ... field study (KB0120) of Zimeta for the control of ... Company. --> --> ...
Breaking Medicine Technology: